Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study
- 19 January 2007
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 191 (2) , 333-339
Abstract
Previous studies have investigated the occupancy of the serotonin reuptake transporter (SERT) after clinical doses of citalopram and other selective serotonin reuptake inhibitors. In the present study, the occupancies of SERT after multiple doses of escitalopram and citalopram were compared using the radioligand [123I]ADAM and single photon emission computed tomography (SPECT). Fifteen healthy subjects received escitalopram 10 mg/day (n = 6) or citalopram 20 mg/day (n = 9) for a total of 10 days. SERT occupancies in midbrain were determined with SPECT and [123I]ADAM at three different time points: at baseline (no medication) and at 6 and 54 h after last drug intake. At 6 h after the last dose, mean SERT occupancies were 81.5 ± 5.4% (mean±SD) for escitalopram and 64.0 ± 12.7% for citalopram (p < 0.01). At 54 h after the last dose, mean SERT occupancies were 63.3 ± 12.1% for escitalopram and 49.0 ± 11.7% for citalopram (p < 0.05). The plasma concentrations of the S-enantiomer were of the same magnitude in both substances. For both drugs, the elimination rate of the S-enantiomer in plasma was markedly higher than the occupancy decline rate in the midbrain. The significantly higher occupancy of SERT after multiple doses of escitalopram compared to citalopram indicates an increased inhibition of SERT by escitalopram. The results can also be explained by an attenuating effect of R-citalopram on the occupancy of S-citalopram at the SERT.Keywords
This publication has 22 references indexed in Scilit:
- Time Course of In Vivo 5-HTT Transporter Occupancy by FluvoxamineJournal of Clinical Psychopharmacology, 2006
- Imaging of serotonin transporters and its blockade by citalopram in patients with major depression using a novel SPECT ligand [123I]-ADAMJournal of Neural Transmission, 2006
- A randomized, double-blind, 24‐week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorderCurrent Medical Research and Opinion, 2005
- Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorderInternational Clinical Psychopharmacology, 2005
- Regional distribution of serotonin transporter protein in postmortem human brainNuclear Medicine and Biology, 2005
- Unique mechanism of action for escitalopram: does it hold the promise?International Journal of Psychiatry in Clinical Practice, 2004
- Significant dissociation of brain and plasma kinetics with antipsychoticsMolecular Psychiatry, 2002
- World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and Continuation Treatment of Major Depressive DisorderThe World Journal of Biological Psychiatry, 2002
- CitalopramCNS Drugs, 1997
- The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patientsActa Psychiatrica Scandinavica, 1987